Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy. Of 102 patients placed into the study, 85 were determined to comprise the adequately treated group (ATG): a full course of radiotherapy and two cycles of BCNU chemotherapy. Within the ATG, those patients who received levamisole did not demonstrate significantly different serial delayed hypersensitivity reactions, peripheral blood lymphocyte and T-cell counts, or serum IgM levels, compared to those patients not receiving levamisole. There was no significant difference in survival times of the two groups. Studies utilizing the avian sarcoma virus-induced glioma in rats also showed no improvement in survival with levamisole stimulation as the only immune agent, but the combination of active immunization and adjuvant stimulation with bacillus Calmette-Guerin plus levamisole was found to be therapeutically effective in this model and will be used in future pilot studies of active immunization in patients.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001355:Alpharetrovirus; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology; D002330:Carmustine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011897:Random Allocation; D051381:Rats
D000276:Adjuvants, Immunologic; D007978:Levamisole; D002330:Carmustine